Uli Hacksell has over 20 years of international management experience from both large pharmaceutical and biotech companies. He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public multibillion dollar company listed on the NASDAQ.

Uli Hacksell, Ph.D. Board member since 2017. Action Pharma A/S and the Swedish Medical Products Agency. He currently serves as Chairman of the Board of Directors at Cerecor, Inc. and is a Member of the Board of Directors at InDex Pharmaceuticals AB and Uppsala University.

Uli Hacksell har tidigare varit vd för forskningsbolaget Medivir och har under 90-talet innehaft seniora positioner vid Astra, numera Astra Zeneca. Han är för närvarande även styrelsemedlem i bland annat forskningsbolagen Active Biotech, Index Pharmaceuticals och Medivir. För närvarande har Uli Hacksell inga aktier i Synact Pharma. Shareholders of SynAct Pharma proposes Uli Hacksell as new board member Tue, Oct 20, 2020 11:42 CET. Shareholders together representing more than 20 per cent of the shares and votes in the company has announced that they propose Uli Hacksell to be elected as new board member of SynAct Pharma. For this reason, the board of directors will convene an extraordinary shareholders’ meeting to be Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University.Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and biotech companies as well as more than 10 years experience as CEO of publicly owned companies. He is currently board member of Active Biotech AB (publ), Beactica Therapeutics AB, InDex Pharmaceuticals Uli Hacksell, Ph.D.

Uli hacksell action pharma

Uli Hacksell has over 20 years of international management experience from both large pharmaceutical and biotech companies. He was the CEO of ACADIA Pharmaceuticals from September 2000 to March 2015, and led the company from a private start-up to becoming a public multibillion dollar company listed on the NASDAQ. 2007-06-22 · With the pipeline this company has, Cramer thinks this $14 stock could hit $20 by this time next year.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home July 9, 2015 - InDex Pharmaceuticals today announced that Uli Hacksell and Jesper Wiklund have been appointed as new members of the Board of Directors. Professor Hacksell and Mr Wiklund together Den 6 november meddelade SynAct Pharma att Uli Hacksell valdes till ny ordinarie styrelseledamot. Den 9 november tillkännager SynAct Pharma positiva interimsdata från fas 2-studien med AP1189 i reumatoid artrit Dr Hacksell has over 20 years’ experience of international management from both large pharma and small biotech companies, with recent CEO positions at two NASDAQ-listed companies: Cerecor Inc. and ACADIA Pharmaceuticals Inc. During his 15 years at ACADIA he led the business from a private start-up to becoming a public multibillion dollar company. The company announces plans to reduce activities not critical to its development pipeline of drug candidates as part of its enhanced focus on clinical stage projects, it lays off 60 jobs and replaces the CEO, Christine Lind, with acting CEO Uli Hacksell.

Prepared Santaris for US Nasdaq IPO Holdings: 511,430 4 SynAct Pharma –Experienced Management Thomas Boesen, PhD –COO 20 years experience from Biotech and Pharma Industry Inventor of several new chemical entities Co-Founder of TXP Pharma Former VP Discovery, Action Pharma Shareholders of SynAct Pharma proposes Uli Hacksell as new board member. Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University. Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and bi Acadia Pharmaceuticals Inc said it redesigned an ongoing late-stage study on its experimental anti-psychotic drug for Parkinson's disease patients, and that it plans to conduct an identical study Which company executives are buying and selling shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) stock?

Notice of extraordinary shareholders' meeting in SynAct Pharma AB. 2020-10-20 · Shareholders of SynAct Pharma proposes Uli Hacksell as new board member.

aktiebolagslagen (2005:551)). Uli Hacksell.

Uli Hacksell is considered to be independent in relation to SynAct as well as its senior management and in relation to major shareholders. Other information The shareholders' are reminded of their right to request information at the shareholders' meeting pursuant to chapter 7 section 32 paragraph 1 of the Swedish Companies Act ( Sw . aktiebolagslagen (2005:551)).

Uli Hacksell, born 1950, is a trained pharmacist and holds a PhD from Uppsala University.Uli Hacksell has more than 25 years experience from senior positions in both large pharmaceutical and biotech companies as well as more than 10 years experience as CEO of publicly owned companies.

SynAct Pharma AB is a biotechnology company aiming to develop new medicine for the treatment of inflammatory diseases. Action Pharma A/S. Dr Uli Hacksell. Medivir AB. Dr John Haurum. View More. EXHIBIT 10.24 .
Asperger spektrum symptome

aktiebolagslagen (2005:551)). Uli Hacksell. Born: 1950 Title: Member of the Board since 2018.. Education: PhD at Uppsala University. Background: Senior positions in major pharmaceutical and biotech companies for over 25 years and more than 10 years’ experience as the CEO of publicly owned companies.

Uli Hacksell Cyclocondensation of 2-(2-cyano-1,2-diphenylethyl)quinuclidin-3-one 1 in the presence of sulfuric acid gave an intramolecular phenylation instead of lactam formation. Uli Hacksell. Född: 1950.
David hansson

1 pdf
fungerar munskydd
personcentrerad vard en karnkompetens for god och saker vard
restaurang personsökare
kierkegaard y schopenhauer
executive assistant lon

Uli Hacksell, Ph.D. Board member since 2017. Action Pharma A/S and the Swedish Medical Products Agency. He currently serves as Chairman of the Board of Directors at Cerecor, Inc. and is a Member of the Board of Directors at InDex Pharmaceuticals AB and Uppsala University.

Uli Hacksell Hacksell, född 1950, har under 30 år arbetat inom farmaceutisk industri och bioteknikbolag. Som vd för San Diego-baserade ACADIA Pharmaceuticals (2000-2015) ledde han utvecklingen från privat start-up företag till publikt mångmiljardbolag och framtagandet av det första och enda godkända läkemedlet mot psykos hos Parkinsonpatienter. Login Problem!